Financial Performance - For the six months ended September 30, 2021, the Global X MSCI China ETF reported a net loss of HK$150,413,971, compared to a profit of HK$225,654,532 in the same period of the previous year[7]. - The Global X CSI 300 ETF experienced a net loss of HK$3,485,394 for the six months ended September 30, 2021, compared to a profit of HK$2,080,241 in the prior year[7]. - The Global X China Cloud Computing ETF reported a net loss of HK$332,324,137 for the six months ended September 30, 2021[7]. - The Global X Hang Seng High Dividend Yield ETF reported a loss before tax of HK$3,485,404 for the six months ended 30 September 2021, compared to a profit of HK$2,080,241 in the same period of 2020[12]. - The total comprehensive income for the Global X MSCI China ETF was a loss of HK$150,413,971 for the period, contrasting with a profit of HK$225,654,532 in the previous year[8]. - Global X China Biotech ETF reported a loss before tax of RMB 91,204,697 for the six months ended 30 September 2021, compared to a profit of RMB 395,174,068 in the same period of 2020, indicating a significant decline in performance[16]. - Global X China Cloud Computing ETF experienced a loss before tax of RMB 332,223,227 for the same period, contrasting with a profit of RMB 246,444,305 in the prior year, reflecting a substantial downturn[18]. Asset and Liability Overview - As of September 30, 2021, total assets for the Global X MSCI China ETF amounted to HK$799,536,756, while the Global X Hang Seng High Dividend Yield ETF had total assets of HK$995,345,599[5]. - Total liabilities for the Global X China Cloud Computing ETF were RMB 26,513,639 as of September 30, 2021[5]. - The total net assets attributable to unitholders for the Global X China Biotech ETF were RMB 34,381,897 as of September 30, 2021[5]. - The total net assets attributable to unitholders at the end of the period for Global X MSCI China ETF were HK$799,124,560, a decrease from HK$995,159,184 at the beginning of the period, reflecting a decline of approximately 19.7%[8]. Cash Flow and Operations - The cash generated from operations for the Global X MSCI China ETF was HK$27,911,986, significantly lower than HK$230,898,259 in the previous year, indicating a decrease of approximately 87.9%[10]. - The net cash flows generated from operating activities for the Global X Hang Seng High Dividend Yield ETF were negative at HK$88,755,800, compared to positive cash flows of HK$14,031,697 in the previous year[12]. - Cash generated from operations for Global X China Biotech ETF was RMB 171,673,868, a recovery from a cash used in operations of RMB 716,020,496 in the previous year[16]. - Global X China Cloud Computing ETF reported cash used in operations of RMB 145,925,293, an improvement from RMB 720,654,827 in the previous year[18]. Management Fees and Expenses - The management fee for the Global X MSCI China ETF was HK$820,522 for the six months ended September 30, 2021[7]. - The management fee for the China Biotech ETF rose to RMB 6,457,134 in the period ended 30 September 2021, compared to RMB 3,574,594 in the previous year[95]. - The total management fee for the Hang Seng High Dividend Yield ETF was HK$144,013 for the period ended 30 September 2021, compared to HK$110,964 in the same period of 2020[95]. - The management fee for the Hang Seng High Dividend Yield ETF and China Biotech ETF was set at 0.68% effective October 1, 2021, while the China Cloud Computing ETF will adopt the same fee structure effective November 1, 2021[143]. Investment Holdings and Portfolio Composition - As of September 30, 2021, Alibaba Group Holding Ltd accounted for 10.29% of the MSCI China ETF's net asset value, while Tencent Holdings Ltd accounted for 12.66%[134]. - The MSCI China ETF holds a total fair value of HK$ 7,999,999,999 across various listed equities as of September 30, 2021[145]. - The investment strategy focuses on high-growth sectors, with a significant allocation to renewable energy and technology firms[146]. - The portfolio includes a diverse range of sectors, including technology, healthcare, and energy, with notable investments in companies like China National Chemical-A and China Shenhua Energy Co-A[146]. - The total fair value of financial assets at fair value through profit or loss is HK$120,074,313, representing 15.08% of net assets[153]. Changes in Holdings - The total closing holdings for the MSCI China ETF as of September 30, 2021, amounted to 923,017 million for China Petroleum & Chemical Corp, down from 1,000,546 million at the beginning of the period, reflecting a decrease of approximately 7.7%[175]. - The closing holdings for Want Want China Holdings Ltd decreased from 203,792 million to 183,177 million, representing a decline of approximately 10.2%[175]. - The total closing holdings for the energy sector, particularly for PetroChina Co Ltd-H, decreased from 878,648 million to 803,483 million, reflecting a decline of approximately 8.5%[175]. - The total closing holdings for the China Biotech ETF included 20,060,000 shares of Sino Biopharmaceutical, with a decrease of 4,731,000 shares from previous holdings[200]. Taxation and Regulatory Considerations - The Sub-Funds did not accrue any PRC Corporate Income Tax (CIT) and Value-Added Tax (VAT) provisions for gains made on China A-shares through RQFII quotas[128]. - The Sub-Funds were subject to a 10% PRC withholding income tax on dividend income received from China A-shares and H-shares[128]. Market Strategy and Economic Conditions - The ETF's performance is closely tied to the overall market trends in China, reflecting the economic conditions and regulatory environment[145]. - The overall market strategy appears focused on maintaining liquidity while selectively increasing positions in high-performing sectors such as energy and consumer staples[192].
中绿(00904) - 2022 - 中期财报